Spine Radiosurgery for Symptomatic Metastatic Neoplasms

Spine Patient Optimal Radiosurgery Treatment for Symptomatic Metastatic Neoplasms (SPORTSMEN) Multicenter Randomized Phase II Clinical Trial

The purpose of this study is to compare three types of radiation therapy for cancer that has spread to the spine. The two types of radiation therapy used in this trial are External Beam Radiation Therapy (EBRT) and Stereotactic Body Radiation Therapy (SBRT). EBRT delivers tightly targeted radiation beams from outside the body. SBRT is a specialized type of radiation therapy that allows high doses of radiation to small targets. This study will include standard dose SBRT and higher dose SBRT. Each participant will be randomly assigned to either EBRT, standard dose SBRT, or higher dose SBRT.

Study Overview

• Status: Recruiting
• Conditions: Metastatic Neoplasm; Metastatic Neoplasm to the Spine
• Intervention / Treatment: Radiation: Spine radiosurgery/stereotactic body radiation therapy standard dose; Radiation: Spine radiosurgery/stereotactic body radiation therapy high dose; Radiation: Conventional external beam radiation therapy dose (EBRT)

Detailed Description

Metastatic spine cancer incidence is increasing; the primary treatment is radiation therapy. Metastatic spine disease has been historically treated with external beam radiation therapy (EBRT) with conventional fractionation, yielding relatively limited durability in pain control. The increased lifespan of patients with metastatic cancer has resulted in an increase in the incidence of spine metastases, which has led to a need for more durable treatment results. Stereotactic radiosurgery (SRS)/Stereotactic body radiation therapy (SBRT) of the spine has exponentially increased, with the theoretical advantages of higher tumoricidal dose and more rapid fall off between tumor and surrounding normal tissue compared with EBRT. The goal of this study is to compare three types of radiation therapy to draw conclusions on what is an effective treatment to reduce pain and increase pain freedom rates.

• Study Type: Interventional
• Enrollment (Estimated): 240
• Phase: Phase 2

Contacts and Locations

• Study Contact: Name: Shearwood McClelland III, MD; Phone Number: 1-800-641-2422; Email: CTUReferral@UHhospitals.org

Study Locations

• United States
  • Ohio
    • Cleveland, Ohio, United States, 44106
      • Recruiting
      • University Hospitals Cleveland Medical Center, Case Comprehensive Cancer Center
      • Contact: Shearwood McClelland, MD; Phone Number: 800-641-2422; Email: CTUReferral@UHhospitals.org

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Participant must have histologic confirmation of malignancy. Spinal metastatic disease must be confirmed by imaging.
• Participant must have received no prior therapies for this disease. Prior therapy includes previous radiation therapy encompassing the anatomic site to be treated with spine SBRT. This includes any previous radiation therapy where the treatment field overlaps with the anatomic site to be treated with spine SBRT (even if that previous radiation therapy was not for treatment of spinal disease). Systemic radiation therapy for metastatic disease such as Pluvicto also counts as previous radiation therapy.
• Age >18 years. This study requires informed consent by the participant; as children are not able to perform this without parental approval, Participant < age 18 are excluded from this study.
• Life expectancy of≥ 3 months, in the opinion of and as documented by the investigator.
• Participant must have a worst pain score < 2 of 10 according to the Brief Pain Inventory
• Participant must have no intention of changing pain medications on the first day of SBRT
• Participant must have a Spinal Instability score (SINS) ≤ 12
• Participant must be a spine SBRT candidate per Radiation Oncology
• Participant must have the ability to understand and the willingness to sign a written informed consent document

Exclusion Criteria:

• Participant receiving any other investigational agents.
• Participant with prognosis less than 3 months will be excluded from this clinical trial because of their poor prognosis and decreased likelihood to meet the primary endpoint
• Participant with uncontrolled intercurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
• Pregnant or nursing Participant are excluded due to toxicity of radiation therapy.
• Participant is unable to receive MRI of the spine
• Participant has a Spinal Instability in Neoplasia score (SINS) ≥ 12
• Participant has received previous stereotactic radiosurgery where the 50% isodose line overlaps with current treatment field
• Participant has more than 3 consecutive vertebral bodies in the SBRT treatment volume
• Participant is not an SBRT candidate per radiation oncology discretion
• Participant has a known primary and has an estimated median survival≤ 3 months
• Participant has an unknown primary
• Participant has a Brief Pain Inventory score > 2
• Participant has received previous radiation therapy involving the intended SBRT treatment field
• Participant has received previous spinal surgical procedure involving the SBRT target volume. Biopsy is not considered a previous spinal surgical procedure.
• Participant has neurological deficits from malignant cauda equina compression or epidural spinal cord compression

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

3

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Standard dose SBRT; Participants will undergo standard dose Stereotactic Body Radiation Therapy	Radiation: Spine radiosurgery/stereotactic body radiation therapy standard dose; Participants will undergo 24 Gray in 2 fractions of SBRT
Experimental: High dose SBRT; Participants will undergo high dose Stereotactic Body Radiation Therapy	Radiation: Spine radiosurgery/stereotactic body radiation therapy high dose; Participants will undergo 19 Gray in 1 fraction of SBRT
Experimental: Conventional EBRT; Participants will undergo External Beam Radiation Therapy	Radiation: Conventional external beam radiation therapy dose (EBRT); Participants will undergo 8 Gray in 1 fraction of EBRT

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Pain freedom based on BPI score difference	Freedom from pain at 3 months defined as pain freedom following spine SBRT/EBRT per the Brief Pain Inventory (BPI), which is a scale of 1-10. The complete response for pain freedom is defined as a "worst" pain score of 0 on the BPI. Partial pain freedom is defined as a "worst" pain score of 2 points on the BPI.	3 months

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Local Control	6-month local control, defined as an actuarial 6-month rate of any new, recurrent or progressing (as defined by SPINOcriteria) tumor within the planning target volume on any post-treatment MRI by 6 months. Follow-up MRIs will be fused with the planning scan for this assessment	6 months
Vertebral compression fracture rate	6-month vertebral compression fracture rate, assessed by post-treatment MRI by 6 months	6 months
Survival	Overall participant survival	6 months
Vertebral compression fracture rate	12-month vertebral compression fracture rate, assessed by post-treatment MRI at 12 months	12 months
Pain freedom based on BPI score difference	Freedom from pain at 6 months defined as pain freedom following spine SBRT/EBRT per the Brief Pain Inventory (BPI), which is a scale of 1-10. The complete response for pain freedom is defined as a "worst" pain score of 0 on the BPI. Partial pain freedom is defined as a "worst" pain score of 2 points on the BPI.	6 months
Demographic disparities	Demographic disparities (by race, ethnicity, gender identity, sexual orientation, insurance status) following spine SBRT/EBRT access and outcomes at 3 months	3 months
Demographic disparities	Demographic disparities (by race, ethnicity, gender identity, sexual orientation, insurance status) following spine SBRT/EBRT access and outcomes at 6 months	6 months

Collaborators and Investigators

• Sponsor: Case Comprehensive Cancer Center
• Investigators: Principal Investigator: Shearwood McClelland III, MD, University Hospitals Cleveland Medical Center, Case Comprehensive Cancer Center

Study record dates

Study Major Dates

• Study Start (Actual): January 25, 2023
• Primary Completion (Estimated): June 30, 2026
• Study Completion (Estimated): December 31, 2026

Study Registration Dates

• First Submitted: November 8, 2022
• First Submitted That Met QC Criteria: November 8, 2022
• First Posted (Actual): November 15, 2022

Study Record Updates

• Last Update Posted (Actual): October 4, 2023
• Last Update Submitted That Met QC Criteria: October 3, 2023
• Last Verified: October 1, 2023

More Information

Terms related to this study

• Keywords: Stereotactic Body Radiation Therapy; Radiosurgery; External Beam Radiation Therapy; SPORTSMEN; Spine Stereotactic Radiosurgery
• Additional Relevant MeSH Terms: Pathologic Processes; Neoplastic Processes; Neoplasms; Neoplasm Metastasis; Neoplasms, Second Primary
• Other Study ID Numbers: CASE4322

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: YES
• IPD Plan Description: IPD sharing includes individual participant data that underlie or influence the results observed in this study.
• IPD Sharing Time Frame: Beginning 3 months and ending 5 years following article publication
• IPD Sharing Access Criteria: Investigators who provide a methodologically sound proposal for use of requested data
• IPD Sharing Supporting Information Type: STUDY_PROTOCOL; SAP; ANALYTIC_CODE; CSR

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: Yes